Dihydroorotate Dehydrogenase 1 pc x 10 mg

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Primary TargetDHODH

Cell permeable: yes

General description

A quinolinecarboxylic acid derivative with immunosuppressive and anti-neoplastic properties. Inhibits pyrimidine synthesis by blocking the activity of mammalian mitochondrial dihydroorotate dehydrogenase (DHODH; IC₅₀ = 12 nM). Does not affect DHODH in non-mammalian species. Also reported to inhibit glycosylation of adhesion molecules. Potentiates the sensitivity of U1690 small cell lung cancer cells to TRAIL-induced apoptosis and synergistically enhances the anti-tumor effects of doxorubicin ( ~100 µM).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

He, T. et al. 2013. Oncogene32, in press.Hurt, D.E., et al. 2006. Bioorg. Med. Chem. Lett.16, 1610.Schnellrath, L. et al. 2011. Int. J. Antimicrob. Agents.38, 435.Batt, D.G., et al. 1995. Bioorg. Med. Chem. Lett.14, 1549.Allison, A., et al. 1993. Transplantation Proc.25, 67.Cramer, D. et al. 1992. Transplantation.53, 303.

Packaging

Packaged under inert gas

10 mg in Glass bottle

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)